Gotowe bibliografie tematyczne / 811/.54

Gotowa bibliografia na temat „811/.54”

Autor: Grafiati
Data publikacji: 26 lipca 2024
Data aktualizacji: 27 lipca 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Spis treści

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „811/.54”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "811/.54"

1

Editor, El. "Septiembre". ECA: Estudios Centroamericanos 54, nr 611 (30.09.1999): 811–18. http://dx.doi.org/10.51378/eca.v54i611.6255.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Grishin, Evgeni, i Hagai B. Perets. "APPLICATION OF GAS DYNAMICAL FRICTION FOR PLANETESIMALS. I. EVOLUTION OF SINGLE PLANETESIMALS". Astrophysical Journal 811, nr 1 (16.09.2015): 54. http://dx.doi.org/10.1088/0004-637x/811/1/54.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Tanaka, Chie, Mitsuro Kanda, Koki Nakanishi, Shinichi Umeda, Dai Shimizu, Yoshikuni Inokawa, Hideki Takami i in. "Perioperative changes in geriatric functions of elderly patients undergoing surgical resection for gastric cancer." Journal of Clinical Oncology 41, nr 4_suppl (1.02.2023): 811. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.811.

Pełny tekst źródła
Streszczenie:
811 Background: Little knowledge is available for postsurgical changes in cognitive and physical functions that may be useful for considering indication for surgery in elderly patients with gastric cancer. We therefore conducted a prospective study aimed to determine the influence of gastrectomy on these patients. Methods: We recruited patients older than 75 years for whom gastrectomy for gastric cancer had been planned, and assessed their cognitive and physical functions, daily activities, episodes of depression, confusion, and delirium before surgery (baseline), upon discharge, and at 6 months after surgery (POM 6). Results: Among 54 elderly patients registered between February 2017 and February 2020. There were no significant decreases in MMSE scores between baseline and at POM 6, nor were there significant differences in physical function and indicators of depression and confusion between these time points. As many as 20% of patients were found to have the functional decline on the basic activities of daily living scores (BADL) after surgery compared with the baseline. The only variable significantly associated with a functional decline in BADL was postoperative complications. Conclusions: Postoperative cognitive functions did not significantly decline when compared with the baseline scores, although postoperative BADL scores of patients who experienced postoperative complications were significantly lower than those who did not.
Style APA, Harvard, Vancouver, ISO itp.
4

Venkatesh, V. C., B. C. Planer, M. Schwartz, J. N. Vanderbilt, R. T. White i P. L. Ballard. "Characterization of the promoter of human pulmonary surfactant protein B gene". American Journal of Physiology-Lung Cellular and Molecular Physiology 268, nr 4 (1.04.1995): L674—L682. http://dx.doi.org/10.1152/ajplung.1995.268.4.l674.

Pełny tekst źródła
Streszczenie:
Pulmonary surfactant protein B (SP-B) is required for normal surfactant function and for survival at birth. To further study SP-B gene expression, we sequenced genomic clones and examined promoter activity of SP-B DNA fragments by transient transfection. A plasmid construct containing human SP-B fragment -1039/+431 linked to chloramphenicol acetyltransferase (CAT) reporter gene was readily expressed in H441 cells, which are derived from a human lung adenocarcinoma, but was < 4% as active in Hep G2, HeLa, and Calu 6 cell lines. SP-B promoter activity in H441 cells was orientation dependent and increased by linked Rous sarcoma virus (RSV) enhancer and was stronger than for thymidine kinase (tk) and RSV promoters. Deletional mapping of the 5' flanking region with exonuclease III suggested nonspecific negative (-811/-1039)- and positive (-453/-641)-control regions and a cell-specific enhancer region at -208 to -54. When a fragment from -403 to -35 base pairs (bp) was placed upstream or downstream of tkCAT, in either orientation, expression in H441 cells but not other cell lines was increased 4- to 28-fold relative to tkCAT. Deletional analysis of the 3' terminus indicated a requirement for at least 7 bp 3' of the transcription start site. Promoter activity was strongly inhibited in a dose-dependent fashion by phorbol ester, with responsiveness mapped to bp -208/-54, but was not responsive to glucocorticoid.(ABSTRACT TRUNCATED AT 250 WORDS)
Style APA, Harvard, Vancouver, ISO itp.
5

Kambhampati, Swetha, Kelly Bauer, Jimmy Hwang, Andrea Grace Bocobo, John Dozier Gordan i Robin Kate Kelley. "Nivolumab in advanced hepatocellular carcinoma (HCC) and Child Pugh B (CPB) cirrhosis: Safety and clinical outcomes in a retrospective case series." Journal of Clinical Oncology 36, nr 4_suppl (1.02.2018): 496. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.496.

Pełny tekst źródła
Streszczenie:
496 Background: HCC patients (pts) with Child Pugh B (CPB) cirrhosis have poor prognosis and limited treatment (Tx) options. Nivolumab demonstrated durable responses and acceptable safety in Child Pugh A (CPA) HCC in the CheckMate-040 trial with rates of hepatotoxicity similar to non-HCC populations. The safety and efficacy of nivolumab has not been established in pts with CPB cirrhosis. Methods: Design: Retrospective case series with IRB approval. Key eligibility: HCC with CPB cirrhosis; treated with nivolumab as standard Tx; enrolled in the UCSF Hepatobiliary Tissue Bank and Registry. Study endpoints: Safety during nivolumab Tx including all-cause grade(Gr) ≥ 3 adverse events (AE), serious AE (SAE), any grade immune-related (ir)AE, and systemic steroid (SS) requirement; clinical outcomes including time on Tx (TOT) with nivolumab and overall survival (OS). Results: Thirteen pts were included: male 77%; Asian 38%, white 54%; median age 66 (range: 26-86); HCV Ab+ 31%, HBsAg+ 23%; BCLC B/C 31%/69%; median Child-Pugh score 8; median prior systemic Tx 1 (range: 0-6); prior sorafenib 69%, median duration on prior sorafenib 137 days (range 10-341). The Table depicts safety outcomes on nivolumab. Median TOT on nivolumab: 44 days (95% CI: 32, 98) (range: 17-811+). Median OS from start of nivolumab: 119 days (95% CI: 40, 247) (range: 40-811+). Best response of at least stable disease occurred in 3/13 (23%) of patients, including prolonged stable disease (SD) for 6+ months and complete response (CR) for 24+ months on nivolumab (1 pt each). Conclusions: CPB HCC pts treated with nivolumab experienced high rates of all-cause Gr ≥ 3 AE and SAE and short OS, similar to prior studies in CPB HCC. Rates of irAE attributed to nivolumab were similar to rates reported in CheckMate-040 CPA population, without unexpected AE. A subset of pts experienced prolonged stable disease and CR. Nivolumab warrants further study in CPB HCC.[Table: see text]
Style APA, Harvard, Vancouver, ISO itp.
6

Ma, Xiaodong, Shizu Oyamada, Fan Gao, Tim Wu, Michael P. Robich, Hao Wu, Xingwei Wang i in. "Corrigendum to “Paclitaxel/sirolimus combination coated drug-eluting stent: In vitro and in vivo drug release studies” [J. Pharm. Biomed. Anal. 54 (2011) 807–811]". Journal of Pharmaceutical and Biomedical Analysis 59 (luty 2012): 217. http://dx.doi.org/10.1016/j.jpba.2011.10.008.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Doepker, Matthew, Andrea M. Abbott, Ravi Shridhar, Sarah E. Hoffe, Khaldoun Almhanna i Kenneth L. Meredith. "Effect of neoadjuvant therapy on the risk for atrial fibrillation in patients undergoing esophagectomy." Journal of Clinical Oncology 33, nr 3_suppl (20.01.2015): 210. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.210.

Pełny tekst źródła
Streszczenie:
210 Background: Neoadjuvant chemoradiation (NT) has become the standard for patients with locally advanced esophageal cancer. Thirty percent of patients who undergo esophagectomy will develop atrial fibrillation (AF). NT may contribute to patients developing AF and this may be a surrogate for anastomotic dehiscence (AD). Methods: We queried a prospective esophageal database to identify patients who underwent esophagectomy with or without NT. Demographics and post-operative complications were all compared with fisher exact test and considered significant at p<0.05. Results: We identified 811 patients who underwent esophagectomy with a mean age of 68 +/- 12 years. Five-hundred and fifteen (63.5%) were treated with NT and 296 (36.5%) were not. Eighty-nine (11%) of patients developed AF, 59 (11.5%) in the NT group, and 30 (10.1%) in the non NT group. There was no significant differences noted in the incidence of AF in those that were treated with NT and those that were not (p=0.64). A total of 54 (6.7%) patients were identified as having AD, 27 (5.2%) in the NT cohort and 27 (9.1%) in the non NT cohort. The NT group had lower incidence of AD compared to their non NT counterparts (p=0.04). Of the 54 patients who experienced AD, 6 (11%) had concomitant AF, and 48 (89%) did not and the remaining 83 patients who developed AF did not develop AD (p=1). Conclusions: NT prior to esophagectomy does not increase patient’s risk for developing postoperative AF. Moreover, the presence of AF in the post esophagectomy patient, did not serve as a surrogate for identifying AD.
Style APA, Harvard, Vancouver, ISO itp.
8

Intragumtornchai, Tanin, Udomsak Bunworasate, Thanyaphong Na Nakorn i Ponlapat Rojnuckarin. "Alemtuzumab in Combination with CHOP and ESHAP as First-Line Treatment in Peripheral T-Cell Lymphoma." Blood 108, nr 11 (16.11.2006): 4740. http://dx.doi.org/10.1182/blood.v108.11.4740.4740.

Pełny tekst źródła
Streszczenie:
Abstract Patients diagnosed with peripheral T-cell lymphomas (PTCL) generally had a poorer prognosis compared to B-cell non-Hodgkin’s lymphomas. With conventional treatment, the 5-year overall and failure-free survivals (OS and FFS) were 36% and 23%, respectively (Vose et al, Blood2005;106:abstract 811). Between February 2005 and January 2006, 13 consecutive patients newly diagnosed with PTCL (5, extranodal nasal NK/T-cell lymphoma, 4 subcutaneous panniculitis-like, 3 PTCL, unspecified and 1 enteropathy type) were enrolled. The median age was 44 years (range, 21–56) and male:female was 1.6:1. Fifty-four percent had stage III/IV, 31%, PS 2–3, 69%, B-symptoms, 15%, bulky disease, 46%, &gt; 1 extranodal site, 38%, elevated serum LDH and 39%, aaIPI 2–3. Twenty-three percent had thrombocytopenia. Patients were treated with alemtuzumab 30 mg. sc. D1-3 of cycle 1–5 plus CHOP (day 1 of cycle 1, 3, 5) and ESHAP (day 1 of cycle 2, 4, 6) at 28-day intervals. Valacyclovir 500 mg tid and trimethoprim/sulfamethoxazole were given for prophylaxis of CMV and Pneumocystis carinii infection, respectively. Of the evaluable 10 patients, complete remission was obtained in 8 patients, 1 had partial remission and 1 had CNS progression while on treatment. Infection was a major adverse complication: 54% had CMV reactivation (1 had CMV disease), 54%, febrile neutropenia and 15%, tuberculosis. With a median follow-up time of 8 months, the 2-year OS and FFS were 75% (95%CI, 41–92) and 48% (95%CI, 14–76), respectively. From the standpoint of this result, alemtuzumab in combination with CHOP and ESHAP is an effective front-line therapy for patients newly diagnosed with PTCL.
Style APA, Harvard, Vancouver, ISO itp.
9

Gutiérrez Castro, Bleenis, José Luis Fernández, Federico Cassella, Andrés Wonaga i Luis Viola. "Adenoma Detection Rate at Different Age Intervals Suggests Starting Colorectal Cancer Screening at 45 Years of Age". Acta Gastroenterológica Latinoamericana 53, nr 1 (30.03.2023): 59–67. http://dx.doi.org/10.52787/agl.v53i1.292.

Pełny tekst źródła
Streszczenie:
Introduction. It is uncertain whether starting screening at 45 years old would improve colorectal cancer prevention and currently available studies in adults younger than 50 years old are limited. Aim. To evaluate the adenoma detection rate at different age intervals. Materials and methods. Colonoscopies performed on adult outpatients were analyzed. Adenoma detection was recorded in the total population and in patients with screening indication. First, patients were divided into two groups: 50 years or older (group A) and younger than 50 years (group B). Then, we analyzed the different age segments: up to 44 years (group 1) 45 to 49 (group 2), 50 to 54 (group 3), and 55 or older (group 4). Results. A total of 5090 patients were included, 2877 with indication for screening. Patients were divided as follows: 3883 in group A, 1207 in group B, 811 in group 1, 396 in group 2, 749 in group 3 and 3134 in group 4. In the total population, adenoma detection was 20.5%: 23.5% in group A, 10.5% in group B (p = 0.000); 8.3% in group 1, 14.8% ingroup 2, 18.1% in group 3, and 24.8% in group 4 (group 1vs. group 2: p = 0.001, group 2 vs. group 3: p = 0.189, andgroup 3 vs. group 4: p = 0.000). In the screening population,adenoma detection was 20.5%: 21.4% in group A, 14.8%in group B (p = 0.004); 13.1% in group 1, 17.0% in group2, 16.1% in group 3, and 22.8% in group 4 (group 1 vs.group 2: p = 0.31; group 2 vs. group 3: p = 0.81; and group3 vs. group 4: p = 0.001). Conclusion. Adenoma detectionis not different between 45 to 49 and 50 to 54 years of age,and is lower below 45 years of age, which suggests startingcolorectal cancer screening at this age.
Style APA, Harvard, Vancouver, ISO itp.
10

Petrova, Penka, Alexander Arsov, Ivan Ivanov, Lidia Tsigoriyna i Kaloyan Petrov. "New Exopolysaccharides Produced by Bacillus licheniformis 24 Display Substrate-Dependent Content and Antioxidant Activity". Microorganisms 9, nr 10 (10.10.2021): 2127. http://dx.doi.org/10.3390/microorganisms9102127.

Pełny tekst źródła
Streszczenie:
Bacillus licheniformis is a soil bacterium with many industrial applications. In addition to enzymes, platform chemicals, antibiotics and phytohormones, the species produces exopolysaccharides (EPSs) of various biological activities. This study revealed that Bulgarian isolate B. licheniformis 24 produced EPSs consisting of galactose, glucose and mannose with substrate-dependent ratio. From glucose, B. licheniformis 24 secreted EPS1, consisting of 54% galactose, 39% glucose and 7% mannose. From fructose, the strain formed EPS2, containing 51% glucose, 30% mannose and 19% galactose. Batch cultivation in flasks yielded 2.2–2.6 g/L EPS1 and 1.90–2.11 g/L EPS2. Four to five times higher yields of EPS were obtained from both substrates during batch and fed-batch processes in a fermenter at 37.8 °C, pH 6.2 and aeration 3.68 vvm. The batch process with 200 g/L of starting substrates received 9.64 g/L EPS1 and 6.29 g/L EPS2, reaching maximum values at the 33rd and 24th h, respectively. Fed-batch fermentation resulted in the highest yields, 12.61 g/L EPS1 and 7.03 g/L EPS2. In all processes, EPSs were produced only in the exponential growth phase. Both EPSs exhibited antioxidant activity, but EPS2 was much more potent in this regard, reaching 811 μM Vitamin C Equivalent Antioxidant Capacity (versus 135 μM for EPS1). EPS1 displayed antibacterial activity against a non-O1 strain of Vibrio cholerae.
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "811/.54"

1

Hicok, Bob. The legend of light. Madison: University of Wisconsin Press, 1995.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Anzaldúa, Gloria. Borderlands: The new mestiza = La frontera. Wyd. 3. San Francisco: Aunt Lute Books, 2007.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Rich, Adrienne Cecile. The fact of a doorframe: Selected poems, 1950-2001. New York: W.W. Norton, 2002.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Jon, Halper, red. Gary Snyder: Dimensions of a life. San Francisco: Sierra Club Books, 1991.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Gwendolyn, Brooks. Selected poems. Redaktor Alexander Elizabeth 1962-. New York: Library of America, 2005.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Gwendolyn, Brooks. Selected poems. New York: Perennial Classics, 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Ortiz, Simon J. From Sand Creek. Tucson: University of Arizona Press, 2000.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Anzaldúa, Gloria. Borderlands/La Frontera: The New Mestiza. Wyd. 2. San Francisco: Aunt Lute Books, 2012.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Anzaldúa, Gloria. Borderlands / La Frontera: The New Mestiza. Wyd. 2. San Francisco: Aunt Lute Books, 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Noon. Los Angeles: Sun & Moon Press, 1997.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „811/.54” dla poszczególnych typów źródeł:
Artykuły w czasopismach Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii